Cargando…

An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis

PURPOSE: Systemic mastocytosis (SM) is characterized by the expansion of clonal mast cells that infiltrate various organ systems. The extent of organ infiltration and subsequent organ damage distinguishes between indolent SM (ISM) defined by a nearly normal life expectancy and advanced SM (AdvSM) de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riffel, Philipp, Schwaab, Juliana, Lutz, Christopher, Naumann, Nicole, Metzgeroth, Georgia, Fabarius, Alice, Schoenberg, Stefan O., Hofmann, Wolf-Karsten, Valent, Peter, Reiter, Andreas, Jawhar, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085471/ https://www.ncbi.nlm.nih.gov/pubmed/31980928 http://dx.doi.org/10.1007/s00432-019-03119-3

Ejemplares similares

Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
por: Riffel, Julia, et al.
Publicado: (2022)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
por: Lübke, Johannes, et al.
Publicado: (2023)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
por: Jawhar, Mohamad, et al.
Publicado: (2017)

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
por: Metzgeroth, Georgia, et al.
Publicado: (2023)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
por: Jawhar, Mohamad, et al.
Publicado: (2017)

Transcriptomic profiling does not refine mastocytosis diagnosis
por: Buschhorn, Lars, et al.
Publicado: (2023)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms
por: Rotterdam, Jil, et al.
Publicado: (2021)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
por: Kluin-Nelemans, Hanneke C., et al.
Publicado: (2021)

Adverse reactions to food in patients with mastocytosis
por: Pucino, Valentina, et al.
Publicado: (2011)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy
por: Niedoszytko, Marek, et al.
Publicado: (2021)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Massive release of the histamine‐degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients
por: Boehm, Thomas, et al.
Publicado: (2019)

Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis
por: Brockow, Knut, et al.
Publicado: (2021)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases
por: Rotterdam, Jil, et al.
Publicado: (2022)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

A new aberrantly spliced BCR‐ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia
por: Naumann, Nicole, et al.
Publicado: (2022)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo
por: Jann, Johann-Christoph, et al.
Publicado: (2021)

Reverse Transcription Can Critically Impact the Diagnostic Outcome of BCR::ABL1 Quantitative Real-Time RT-PCR
por: Spiess, Birgit, et al.
Publicado: (2023)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium
por: Altrock, Eva, et al.
Publicado: (2023)

Leukocyte DNA damage after reduced and conventional absorbed radiation doses using 3rd generation dual-source CT technology
por: Popp, Henning D., et al.
Publicado: (2016)

Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML
por: Christiani, Eva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t1dup151ui66hgiqairvtkm368